INTRODUCTION
============

Among etiologies of erectile dysfunction (ED), arteriogenic ED is the most common etiology. Considering that increasing population of aging groups have ED, atherosclerosis (AS) originated arteriogenic ED could be the most popular etiology among older groups. Treating ED could be a medical burden \[[@B1][@B2]\].

Considering the pivotal role of preclinical studies in investigating the fundamental mechanism of arteriogenic ED with AS, an *in vivo* model that is broadly validated is essential for further research. Currently, there is limited report on such effort. Moreover, there exist difficulties regarding feasibility and reproducibility of such model in the literature \[[@B3][@B4][@B5][@B6][@B7][@B8][@B9][@B10]\]. Furthermore, reported models have limitations including no endothelial dysfunction unless genetic modification or a special diet is required to evoke endothelial injury. Inducing mechanical injury is feasible by ligation or clamping of iliac arteries \[[@B3][@B4][@B5]\]. However, to induce endothelial dysfunction is not easy. Moreover, ligation or clamping is far from physiologic AS which reflects progressive luminal narrowing.

To overcome limitations of previous studies validating an aging arteriogenic ED model, we adopted chronic pelvic ischemia (CPI). Our previous experience has shown that such CPI model is a sound *in vivo* model of an aging ischemic bladder \[[@B11][@B12][@B13][@B14]\]. In addition, we have examined an arteriogenic ED model with AS in a pilot preclinical study \[[@B15]\].

The aim of the present study was to validate our novel arteriogenic ED model with AS based on molecular and histologic evidence and determine the effect of treatment with a phosphodiesterase-5 (PDE-5) inhibitor.

MATERIALS AND METHODS
=====================

1. Animal subjects
------------------

Male Sprague--Dawley rats (400--450 g) at 16 weeks of age were obtained, randomized, and acclimated for two weeks in plastic cages (two rats per cage). Rats were provided free access to purified water and standard compressed feed. Room air temperature was maintained at 22℃±1℃ and light was provided from 7 a.m. to 7 p.m.

2. Ethics statement
-------------------

This study was approved by the Institutional Animal Care and Use Committee of Korea University (No. KUIACUC-20130523-3). Animal handling followed animal experimentation guide provided by the Animal Laboratory of Korea University, Ansan Hospital.

3. Experimental protocols
-------------------------

There were three experimental groups: untreated sham-operated rats with a regular diet (Group I, control \[n=7\]), CPI with cholesterol diet (Group II, ischemia \[n=6\]), and CPI model with cholesterol diet and mirodenafil treatment (Group III, ischemia with treatment \[n=7\]). Rats of Groups II and III received an endothelial injury of iliac arteries and 2% cholesterol diet for eight weeks. Group I rats underwent a sham operation. They were maintained with a regular diet. Groups II and III rats received an endothelial injury with cholesterol diet during the eighth week. Eight weeks after operation, Group III rats were fed with mirodenafil plus normal saline for four weeks. Group II rats were fed with normal saline only. Twelve weeks after operation, *in vivo* measurements of parameters associated with erectile function (maximum intracavernous pressure \[ICP\] and ICP/mean arterial pressure \[MAP\]) were performed. Mirodenafil (5-Ethyl-3,5-dihydro-2-\[5-(\[4-(2-hydroxyethyl)-1-piperazinyl\]sulfonyl)-2-propoxyphenyl\]-7-propyl-4H-pyrrolo\[3,2-d\]pyrimidin-4-one) was provided by SK Chemical Ltd. (Seoul, Korea) with a purity of 99%. We dissolved mirodenafil using 40% polyethylene glycol-electrolyte solution in water and used it at a dose of 20 mg/kg. The solution (0.3--0.5 mL) was administered *via* an oral Zonde needle.

4. *In vivo* chronic pelvic ischemia model
------------------------------------------

An *in vivo* CPI model followed the original model introduced by Nomiya et al \[[@B11][@B12][@B13][@B14]\]. After general anesthesia using isoflurane (1.5%--2.5%), an inguinal incision was made. Exposure of the iliac fossa and femoral artery was made and a 2-Fr Fogarty arterial embolectomy catheter (E-060-2F; Edwards Lifesciences LLC, Irvine, CA, USA) was inserted through a small incision in the femoral artery. After upward placement of the catheter to the fossa area, air inflation (0.2 mL) was done and pulled downward to the initiation location of the femoral artery. This manual pulling down was repeated 10 times to induce mechanical intimal injury. The same approach was performed on the contralateral region. For the control group, a sham operation was done in the same manner without inducing mechanical intimal injury.

5. *In vivo* measurement of intracavernous pressure
---------------------------------------------------

*In vivo* measurement of ICP was performed under general anesthesia with isoflurane (1.5%--2.5%) at 12 weeks after establishment of CPI or sham CPI operation. To measure MAP, a 24-gauge angiocatheter was inserted into the left carotid artery. After exposure of the penis corpus cavernosum, an incision was extended to the low abdominal area to introduce the bladder and prostate. A 22-gauge needle was inserted into the corpus cavernosum artery and connected to a polyethylene tube (PE 50; Clay Adams, Parsippany, NJ, USA). After visual confirmation of the right major pelvic ganglion, a bipolar electrical stimulator (Grass SD9; Grass Instrument, Quincy, MA, USA) was placed and the cavernosal nerve was stimulated for 50 seconds with the condition of 5 v, 20 Hz, and 0.5 milliseconds. Two cycles of electrical stimulation were done and the interval of each stimulation was maintained for at least 5 minutes. Main parameters included maximal ICP, ICP/MAP, total ICP, and slope. Measurements were done using AD Instrument PowerLab™ (AD Instrument, Colorado Springs, CO, USA).

6. Western blot analysis
------------------------

Sample preparation was done by homogenizing sample tissues that were kept under −70℃ and centrifuged at 12,000 rpm for 10 minutes. Protein concentrations were determined by Bradford solution (Sigma, St. Louis, MO, USA). The amount of each protein sample loaded was 40 µg. Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis was done for measuring levels of hypoxia inducible factor 1-alpha (HIF-1α), endothelial nitric oxide synthase (eNOS), and transforming growth factor beta-1 (TGF-β1) by western blotting. For HIF-1α and eNOS, 6% SDS acrylamide gel was used with sampling loading amount of 40 µg. For settings of stacking gel and separation gel, −80 V and −100 V were adopted, respectively. For TGF-β1, 12% SDS acrylamide gel was used with sampling loading amount of 40 µg. For settings of stacking gel and separation gel, −80 V and −120 V were adopted, respectively. Transfer was performed using a polyvinylidene difluoride membrane at 150 mA for 90 minutes. Immunoblotting was performed after blocking and incubation with primary antibodies and secondary antibodies. Primary antibodies specific for HIF-1α, eNOS, and TGF-β1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1:200 in Tris-buffered saline, 0.1% Tween 20 buffer were incubated with the membrane overnight. Actin antibody (Cell Signaling, Danvers, MA, USA) was used at a dilution of 1:3,000 in 2.5% skim milk. It was incubated with the membrane at room temperature for 1 hour. For secondary antibodies, anti-rabbit (Sigma) was used at a dilution of 1:30,000. Finally, developing was done with an enhanced chemiluminescence solution.

7. Vascular histology
---------------------

After obtaining a vascular specimen including abdominal aorta and iliac fossa, histological analysis was done. After fixation with a phosphate-buffered 10% formaldehyde solution, the specimen was used to prepare paraffin block. After preparing paraffin block sections (5 µm in thickness), H&E staining was done. Intimal injury and lumen were then inspected.

8. Masson trichrome staining
----------------------------

After washing fixed fragment of corpus carvernosum, dehydration was done using serial ethanol solution. A paraffin block was made and sectioned to slices (10 µm in thickness). Slice was then placed on a gelatincoated glass for Masson trichrome staining. Quantitative analysis was done using an ECLIPSE Ti-U imaging analysis (Nikon, Tokyo, Japan) and NIS Elements D30 (Nikon). Calculation of smooth muscle (SM)/collagen ratio was done by repeating measurements 10 to 15 times under magnifying powers of 40 or 200.

9. Statistical analysis
-----------------------

All data are described as mean±standard deviation. For analytic method, one-way ANOVA test was used. To simulate non-parametric test, a Kruskal--Wallis test was conducted. Differences were considered significant at p\<0.05. All analyses were performed using STATA ver. 14 (Stata Corp. LP, College Station, TX, USA).

RESULTS
=======

1. Intracavernous pressure
--------------------------

Although the slope of each group showed various patterns ([Fig. 1](#F1){ref-type="fig"}), maximal ICP showed prominent differences among groups I, II, and III (at 73.92±22.12 mmHg, 27.50±11.80 mmHg, and 39.68±7.92 mmHg, respectively, p=0.001) ([Table 1](#T1){ref-type="table"}). ICP/MAP showed prominent differences among groups I, II, and III (at 0.5223±0.2158, 0.1590±0.5667, and 0.2815±0.1425, respectively, p=0.002). In post hoc analyses, the maximal ICP, ICP/MAP, total ICP, and total ICP/MAP of group I were higher than those of group II or group III (all p\<0.05). Between groups II and III, only maximal ICP and ICP/MAP showed significant differences (p\<0.05).

2. Western blotting analysis
----------------------------

Densitometry was used to obtain quantitative results of Western blot. Results were normalized to levels of actin ([Fig. 2](#F2){ref-type="fig"}). HIF-1α levels of group II were significantly higher than those of group I or group III (0.9051±0.2286 *vs*. 0.2933±0.0942 or 0.5675±0.2586, p=0.02). eNOS levels of group II were significantly lower than those of group I or group III (0.4527±0.2119 *vs*. 0.7247±0.0339 or 0.7144±0.3097, p=0.04). TGF-β1 levels of group I were significantly lower than those of group II or group III (0.2547±0.0925 *vs*. 0.4807±0.2284 or 0.4718±0.3212, p=0.03). There was no significant difference in TGF-β1 level between groups II and III.

3. Vascular histology
---------------------

A longitudinal section of common iliac arteries (×400) revealed remarked luminal narrowing with intimal thickening and a degenerative change of media in the ischemia group compared to other groups ([Fig. 3](#F3){ref-type="fig"}).

4. Masson\'s trichrome staining
-------------------------------

The SM/collagen ratio of group I was significantly higher than that of group II or III (0.182±0.05 *vs*. 0.0231±0.1918 or 0.0441±0.0712) ([Fig. 4](#F4){ref-type="fig"}). However, there was no significant difference in SM/collagen ratio between groups II and III.

DISCUSSION
==========

There is no doubt that AS is a significant etiology for ED \[[@B1][@B2][@B16]\]. It could be a grave issue for both individuals and public health considering its deep relationship with the aging process. Establishing a validated arteriogenic ED model with AS is the first step to clearly determine the mechanism and potential treatment for arteriogenic ED with AS. Based on our previous pioneer approach on this issue \[[@B15]\], this study demonstrated its validity with molecular and histological evidences, like the first time. To overcome limitations of previous studies on this issue, reviews were done to systematically design this validation study.

The key pathophysiology of AS change lies in obstructing arterial inflow by narrowed lumen due to artherosclerotic lesions \[[@B1][@B4][@B10][@B17][@B18]\]. Hence, without intimal injury, an ED model could not show endothelial dysfunction. The main mechanism of arteriogenic ED with AS could be explained with two components: structural and functional changes. Structural change is induced by impaired arterial flow which results in hypoxia and fibrosis. In this change, TGF-β plays an important role \[[@B4][@B5]\]. Among previous studies, arterial ligation or partial obstruction was a good model to show structural change \[[@B4][@B5][@B10]\]. However, these studies did not try to show functional change associated with endothelial dysfunction. The key mechanism of endothelial dysfunction lies on NOS. Nitric oxide (NO) is involved in anti-inflammation, anti-platelet aggregation, and anti-oxidative function \[[@B8][@B9][@B18]\]. NOS is composed of three isoforms including neuronal NOS (nNOS), eNOS, and inducible NOS. eNOS is in the endothelium of the cavernosal artery. It has a critical role in the endothelial dysfunction mechanism.

Nowadays, these two main components (structural and functional changes) have a tendency to be overlapped \[[@B3][@B18]\]. Hence, validation of a promising ED model should include these two components together. Our model meets this demand well. Structural change was mediated by the progressive narrowing of the arterial lumen which is far more physiologic than previous artificial ligations or obstructions. To induce functional change, our model included a long-term cholesterol diet and progressive narrowing of the arterial lumen by intimal injury. This study had additional benefit by showing functional change. By *in vivo* measurement of ICP, western blotting of molecular markers, and histological analysis, our model was validated as a promising arteriogenic ED model with AS. Moreover, we used male rats at 16 weeks old in the randomization period, meaning that our model could reflect an aging model more properly than other studies.

Another feature of our study was that mirodenafil, a PDE-5 inhibitor, was used as an inner validation tool. Based on its expected effect on ICP, we could conclude that this model was properly established. By integrating all our results, we could conclude that impaired arterial flow was generated and it created secondary cavernosal dysfunction which was manifested by abnormal ICP and increased HIF-1α. This structural change was aggravated, resulting in fibrosis which also affected secondary cavernosal dysfunction and manifested by elevation of TGF-β and decreased SM/collagen ratio. Together with structural change, there was also a functional change in that eNOS was decreased by endothelial dysfunction. One notable finding of our study was that structural change could not be reversed by PDE-5 inhibitor treatment.

Although this study validated a novel ED model, it had several limitations. First, there was no information about the critical role of mRNA, meaning that detailed processes could not be explained. For example, this study could not assert that endothelial dysfunction was preceded by fibrotic change. Second, besides eNOS, there are more molecular markers that can explain functional change, such as nNOS, nerve growth factor, and vascular endothelial growth factor \[[@B3]\]. Third, considering cholesterol resistant features of rat species, other efforts including genetic and longer-term cholesterol diet are needed. Lastly, our control group could not fully show whether characteristics of this model are caused by mechanical injury or cholesterol diet. Hence, additional groups (*i.e.*, a group with real operation plus regular diet and a group with sham operation plus cholesterol diet) are needed to define characteristics of this model in the future.

CONCLUSIONS
===========

This study validated a novel arteriogenic ED model with AS which was successfully induced by CPI based on molecular and histologic evidences. More promising preclinical studies using this model are needed to elucidate the fundamental pathophysiology and treatment for arteriogenic ED with AS.
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![Representative charts of intracavernosal pressure (ICP). Increase in ICP by electrical stimulation was observed in the sham group (n=7; A). Increases in ICP were clearly lower in the chronic pelvic ischemia (CPI) model group (n=6; B). Increases in ICP were higher than the CPI but lower than the sham group in CPI with treated group (n=7, C). The upper curve is mean arterial pressure and the lower curve is ICP.](wjmh-38-345-g001){#F1}

![Expression levels of molecular proteins in corpus cavernosum based on Western blotting. Alpha-smooth muscle actin (α-SMA) was used as a control. HIF-1α: hypoxia induced factor 1-alpha, eNOS: endothelial nitric oxide synthase, TGF-β1: transforming growth factor beta-1.](wjmh-38-345-g002){#F2}

![Longitudinal section of common iliac arteries (H&E, ×400). Luminal narrowing is prominent with intimal thickening in the ischemia group (B) compared to that in the control group (A) and ischemia with treatment group (C). Arrows indicate arterial lumen.](wjmh-38-345-g003){#F3}

![Masson trichrome staining of penile corpus cavernosum (×200). Smooth muscle/collagen ratio of the ischemia group (B) remained significantly lower than that in the control (A). The ischemia with treatment group (C) showed a higher ratio than that in the chronic pelvic ischemia group (middle).](wjmh-38-345-g004){#F4}

###### Comparative analysis of parameters from ICP measurements

![](wjmh-38-345-i001)

  Group                     Category       Maximal ICP            ICP/MAP              Total ICP                    Slope           Total ICP/MAP
  ------------------------- -------------- ---------------------- -------------------- ---------------------------- --------------- ----------------------
  Control                   Mean±SD        73.9214^a,c^±22.1212   0.5223^a,c^±0.2158   3,542.0000^a,c^±1,391.2937   3.1000±2.4674   24.3700^a,c^±10.0201
  Median                    77.3000^a,c^   0.4497^a,c^            3,266.0000^a,c^      2.3100                       18.9900^a,c^    
  Ischemia                  Mean±SD        27.5033^b,c^±11.8015   0.1590^b,c^±0.5667   1,857.7833^c^±910.3737       1.1360±1.0683   7.8602^c^±1.9001
  Median                    29.5100^b,c^   0.1427^b,c^            1,829.5000^c^        0.6070                       7.3921^c^       
  Ischemia with treatment   Mean±SD        39.6871^a,b^±7.9249    0.2815^a,b^±0.1425   1,512.5714^a^±376.6394       0.9768±0.7373   11.9715^a^±3.3952
  Median                    38.4700^a,b^   0.2512^a,b^            1,555.0000^a^        0.7120                       11.7292^a^      
  p-value                                  0.001                  0.002                0.006                        0.059           0.020

ICP: intracavernous pressure, MAP: mean arterial pressure, SD: standard deviation.

^a^Statistically significant between control group and ischemia with treatment group; ^b^statistically significant between ischemia group and ischemia with treatment group; ^c^statistically significant between control group and ischemia group.
